All News

DPGN, lupus, nephritis, GN, glomerulonephritis, biopsy, kidney

Best of 2024: SGLT2 Inhibitor Protective Effects in Lupus

Jack Cush, MD

Systemic lupus erythematosus (SLE) outcomes were assessed based on whether they received sodium-glucose co-transporter 2 inhibitors (SGLT2i), in the setting of comorbid type 2 diabetes (T2D).

Read Article
kidneys

Best of 2024: Efficacy of Biologics in Patients with Chronic Kidney Disease

Jack Cush, MD

A retrospective cohort study of biological disease-modifying antirheumatic drugs (bDMARDs) persistence in rheumatoid arthritis patients with chronic kidney disease, shows the 3 year survival to be under 50% but that all studied biologics were nearly equivalents with regard to safety and efficacy.

Read Article
vaccine.jpg

Best of 2024: Inadequate Zoster Vaccination in Immunocompromised Patients

Jack Cush, MD

A VA study of shows that recombinant zoster vaccine (RZV) vaccination in immunocompromised patients or those receiving immunosuppressive medications is insufficient, given these are high risk individuals.

Read Article
pills-384846_640%20%281%29.jpg

Best of 2024: Analgesic Prescribing in Patients with Inflammatory Arthritis

Jack Cush, MD

A UK cross-sectional EHR clinical practice analysis between 2004 and 2020 shows that analgesic prescribing in inflammatory arthritis patients has declined, but still remains substantial, including opioid prescribing. Data was drawn from the Clinical Practice Research Datalink Aurum to evaluate analgesic prescription annual prevalence in patients with RA, PsA and axSpA and found that analgesic prescribing declined over time but remained common.

Read Article
RheumNow Podcast square

Bah Humbug Vitamin D (12.20.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.

Read Article
"If you want an argument, put two rheumatologists in a room and ask them about steroid tapers. Add a third and you'll have a fight" -P. Merkel at UPA plenary session #ACR24 @RheumNow

Dr. John Cush RheumNow ( View Tweet)

Upadacitinib in GCA. Merkel et al. SELECT-GCA study. Sustained remission week 52 Upa (+26 week steroid) 46% vs PBO (+52 week steroid) 29%. Reduced flare rates with UPA (see picture). Similar to GiACTA results. @RheumNow #ACR24 Abstr#0770 https://t.co/f7OwxAggaf… https://t.co/PUuwo0MLso https://t.co/JBzokT9icx

Links:

Dr. John Cush RheumNow ( View Tweet)
Should you worry about giving TNFi to RA pts after a cancer diagnosis? Medicare data with colorectal, lung, prostate Ca: TNFi pts survival no worse (numerically better) than csDMARDs Cancer pts deserve good RA treatment! #ACR24 ABST0202 Suarez-Almazor @MDAndersonNews @RheumNow… https://t.co/aR75hJQ6YK https://t.co/ptDYCsOpXN
Dr. John Cush RheumNow ( View Tweet)
ANA neg, but ENA pos should we care about that result? PPV 5.5% here (similar to 6% prev @EricFMorand: https://t.co/7Lo0DgHtXT) and how many really needed the serology? Anxiety? Surely pos ENA w neg ANA might be more hassle than help. So what to do?⬇️ #ACR24 ABST1930 @RheumNow… https://t.co/lZ1TJxTqhs https://t.co/itx0TCFFjl

Links:

Dr. John Cush RheumNow ( View Tweet)
Great table re:side effects of even low dose steroids in RA Likely generalizes to other diseases ie PMR, SLE P in prednisone stands for poison! #ACR24 @RheumNow https://t.co/2bFy6dwl96 https://t.co/YDtjSX054I

Links:

Dr. John Cush RheumNow ( View Tweet)
TAPIR study of continuing vs stopping steroids in ANCA vasculitis in remission. Relapse at month 6 in 16% vs 4%. OR 4.22, but low rate in either group. If treated Rituximab, no difference! Merkel et al. @RheumNow #ACR24 Abstr#0774 #ACRbest https://t.co/F9DOBLrjVq https://t.co/BtphAuEopA

Links:

Dr. John Cush RheumNow ( View Tweet)
54K Peptic Ulcers Annually (12.13.2024) https://t.co/18FiQx1YQA https://t.co/32UZi9XafS

Links:

Dr. John Cush RheumNow ( View Tweet)
#ACR24 Year in Review: 💡GLP1i significantly decreased knee OA pain over time (or was it the wt loss itself?🤨) 💡CD19 CAR T-Cell therapy has potential to treat/cure many autoimmune diseases (are risks and $ worth the benefit?) 💡 High risk of CV events within 30 days of gout… https://t.co/g3egOpCYNr https://t.co/KMiOEP7pSg
Dr. John Cush RheumNow ( View Tweet)
RheumNow Live 2025: Feb 8-9, Dallas, TX! 🔬 Don’t miss top experts on Psoriatic Disease: ➡️ A. Ogdie: Preventing PsA ➡️ A. Kavanaugh: Biologic Therapies ➡️ K. Gordon: Head-to-Head Studies Register now! https://t.co/9qnqtpkwpT https://t.co/95TGS56vyA

Links:

Dr. John Cush RheumNow ( View Tweet)
Tocilizumab Efficacy in Giant Cell Arteritis Phenotypes A Spanish Collaborative Group study of Tocilizumab (TCZ) in Giant Cell Arteritis (GCA) demonstrated high efficacy regardless of the different vascular phenotypes treated. https://t.co/8wvSy8555Z https://t.co/vaGt1AylBr

Links:

Dr. John Cush RheumNow ( View Tweet)
Metanalysis of 41 studies, & 5343 AAV pts showed 55% (2890) had infection; 36% w/ severe infxn. This included PJP, aspergillosis, candidiasis, HZ, CMV, etc. Pulmonary most common. Risk factors included older, ESRD, DM, smoking, Renal or lung involvement https://t.co/yHo5BNlbiL https://t.co/R2je32YYGy

Links:

Dr. John Cush RheumNow ( View Tweet)
Best of 2024: Prescription Painkiller Misuse in Chronic Pain Patients https://t.co/AyccRCuAHh https://t.co/RYuvDwHANo

Links:

Dr. John Cush RheumNow ( View Tweet)
Abuse of the Safety-Net 340B Drug Programs Dr. Madelaine Feldman comments on the 340B Drug Pricing Program, a safety-net initiative designed to provide costly therapies to vulnerable populations. She argues that the program has deviated from its original intent, with certain… https://t.co/5rIQHsIeAS https://t.co/rXwQPctHDf
Dr. John Cush RheumNow ( View Tweet)
Tocilizumab Efficacy in Giant Cell Arteritis Phenotypes A Spanish Collaborative Group study of Tocilizumab (TCZ) in Giant Cell Arteritis (GCA) demonstrated high efficacy regardless of the different vascular phenotypes treated. https://t.co/nwCU3qW4PT https://t.co/uhvFDrW5Zz

Links:

Dr. John Cush RheumNow ( View Tweet)
3 biosimilars from Celltrion have received a positive recommendatoin from the CHMP of the EMA for pt), Stoboclo and Osenvelt (denosumab biosimilars), and Avtozma (tocilizumab biosimilar), possibly redefining treatment affordability and accessibility across Europe.… https://t.co/dYXfUSpP5I https://t.co/wLQMXomoVS
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×